Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022 [0.03%]
关于在美国家人中使用15价肺炎球菌结合疫苗和20价肺炎球菌结合疫苗的建议：免疫实践咨询委员会（ACIP）更新推荐意见——美国，2022年
Miwako Kobayashi,Jennifer L Farrar,Ryan Gierke et al.
Miwako Kobayashi et al.
In 2021, 20-valent pneumococcal conjugate vaccine (PCV) (PCV20) (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.) and 15-valent PCV (PCV15) (Merck Sharp & Dohme Corp.) were licensed by the Food and Drug Administration for adults aged...
Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022 [0.03%]
与之前新型冠状病毒高传播期相比，奥密克戎变异株早期阶段疾病严重性和医疗保健利用率的变化趋势——美国，2020年12月—2022年1月
A Danielle Iuliano,Joan M Brunkard,Tegan K Boehmer et al.
A Danielle Iuliano et al.
The B.1.1.529 (Omicron) variant of SARS-CoV-2, the virus that causes COVID-19, was first clinically identified in the United States on December 1, 2021, and spread rapidly. By late December, it became the predominant strain, and by January ...
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022 [0.03%]
第三剂mRNA疫苗在德尔塔和奥密克戎变异株流行期间对成人因新冠肺炎就诊急诊科和门诊诊所及住院的有效性-10州VISION网络地区，2021年8月-2022年1月
Mark G Thompson,Karthik Natarajan,Stephanie A Irving et al.
Mark G Thompson et al.
Estimates of COVID-19 mRNA vaccine effectiveness (VE) have declined in recent months (1,2) because of waning vaccine induced immunity over time,* possible increased immune evasion by SARS-CoV-2 variants (3), or a combination of these and ot...
COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021 [0.03%]
2021年4月4日至12月25日德尔塔和奥密克戎变异株流行期间美国25个辖区未接种疫苗、完成基础免疫以及完成基础免疫且加强接种成人新冠发病和死亡情况分析报告
Amelia G Johnson,Avnika B Amin,Akilah R Ali et al.
Amelia G Johnson et al.
Previous reports of COVID-19 case, hospitalization, and death rates by vaccination status† indicate that vaccine protection against infection, as well as serious COVID-19 illness for some groups, declined with the emergence of the B.1.617....
COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021 [0.03%]
2021年5—11月新冠疫情接种状况和以前感染新冠病毒的病例和住院人数差异——加利福尼亚州和纽约州
Tomás M León,Vajeera Dorabawila,Lauren Nelson et al.
Tomás M León et al.
By November 30, 2021, approximately 130,781 COVID-19-associated deaths, one in six of all U.S. deaths from COVID-19, had occurred in California and New York.* COVID-19 vaccination protects against infection with SARS-CoV-2 (the virus that c...
Erratum: Vol. 71, No. 2 [0.03%]
订正：第71卷，第2期
Notes from the Field: Increased Incidence of Fentanyl-Related Deaths Involving Para-fluorofentanyl or Metonitazene - Knox County, Tennessee, November 2020-August 2021 [0.03%]
田间笔记：2020年11月至2021年8月田纳西州诺克斯县涉para-fluorofentanyl或metonitazene的芬太尼相关死亡增加
Jordan Trecki,Roy R Gerona,Ross Ellison et al.
Jordan Trecki et al.
Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021 [0.03%]
2021年8至12月美国研究接种第三剂辉瑞-BioNTech和Moderna新冠疫苗在免疫功能正常及免疫功能低下成人中预防新冠肺炎住院的有效性
Mark W Tenforde,Manish M Patel,Manjusha Gaglani et al.
Mark W Tenforde et al.
COVID-19 mRNA vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) provide protection against infection with SARS-CoV-2, the virus that causes COVID-19, and are highly effective against COVID-19-associated hospitalization among eli...
Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021 [0.03%]
关于使用杨森（强生）新冠疫苗的最新 interim 推荐意见：免疫实施咨询委员会 美国 2021年12月
Sara E Oliver,Megan Wallace,Isaac See et al.
Sara E Oliver et al.
On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the adenovirus-vectored COVID-19 vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson), and on Febru...